U.S. stocks hit new highs, but structural divergence and policy expectation battles intensify

On May 27th, Eastern Time, the close saw the Dow rise 0.36% to 50,644.28, hitting a record high; the S&P 500 edged up 0.02% to 7,520.36; the Nasdaq rose 0.07% to 26,674.73. For the first time this year, the three major indices all closed at new highs simultaneously. However, chip stocks clearly retreated, dragging down the overall tech sector performance. Goldman Sachs then raised its 2026 year-end target for the S&P 500 from 7,600 to 8,000, citing expected combined earnings per share of $340 for its components in 2026.

The core contradiction in the current U.S. stock market is: high-level index momentum weakening as prices chase higher, with structural divergence becoming the main theme. AI computing power and semiconductor-related stocks, due to large prior gains, face momentum risks, while defensive sectors like healthcare and consumer discretionary begin to attract rotation funds. This macro judgment directly establishes a benchmark for differentiated positioning of five individual stocks. Based on strong corporate earnings expectations, Goldman Sachs remains bullish on U.S. stocks, implying that high-quality, genuinely profitable leading companies still have room to rise.

II. MU—Massive Breakthrough to Over 1 Trillion Market Cap, Risks and Opportunities in Momentum Extremes

Micron is currently the most dynamic among the five stocks, and the significant tension between its fundamentals and stock price performance warrants deep analysis.

Fundamentally, in Q2 fiscal 2026, revenue reached $23.86 billion, exceeding expectations by 24.34%, and Non-GAAP EPS hit $12.20, surpassing forecasts by 38.79%; net profit surged 574% year-over-year. UBS sharply raised its target price by 204% to $1,625, estimating that EPS from 2027 to 2029 will remain robust above $100, with the company generating over $400 billion in free cash flow during the same period.

In terms of stock movement, on May 26th, it soared 19.29% in a single day, closing at $895.88, with a intraday high of $916.80. Its market cap broke above $1 trillion that day. Since the start of the year, the stock has gained 213.9%, significantly outperforming the Philadelphia Semiconductor Index’s 81.8% rise; in May, it increased by 75%, potentially marking the best monthly performance since 1987. Pre-market on May 28th, it jumped over 7% on UBS’s report, breaking $800. However, in the pre-market on May 28th, Micron fell slightly by nearly 3%, reflecting short-term profit-taking pressure.

This is a valuation frenzy driven by AI computing infrastructure. As long as the data center construction boom continues, Micron’s true high-growth performance has yet to fully materialize: Q3 gross margin is expected to further rise to about 81%. Multiple investment banks, including Dongwu Securities and UBS, have collectively raised target prices significantly, expecting demand driven by CEO’s outlook to persist through 2026.

However, concerns about momentum risk are equally important. Technical analysis indicates Micron’s recent move completed a very clear five-wave structure, suggesting potential short-term correction. Some analysts even bluntly say, "It’s too high now; buying at this level is purely gambling." From the perspective of a trillion-dollar market cap, the short-term high-risk chase has been significantly amplified, but the structural growth logic of AI storage chip demand remains relatively solid. The key variables are: first, whether actual profitability can continue to meet the expectations of investment banks; second, whether the supply-demand landscape of global storage chip capacity will change marginally due to capacity expansions by various manufacturers. Currently, it’s more prudent to observe the depth of a correction rather than chase high near $920.

III. JNJ—Low-Key Entry of a Healthcare Giant into an Advantageous Pattern

Beyond the noise of tech stocks, Johnson & Johnson is quietly operating under a different logic—an defensive leader worth deep attention.

Fundamentally, in Q1 2026, revenue reached $10k, slightly above expectations ($24.06B), but net profit was $23.62B, below expectations ($5.24B), mainly due to the impact of biosimilar competition on Stelara and one-time divestment costs. The company has raised its full-year revenue guidance to $100.8 billion, with an expected adjusted EPS of $11.30–$11.50, a modest increase reflecting management’s confidence. Adjusted operating growth is estimated at about 6.1%. The company is focusing on core high-growth areas through divestments like DePuy Synthes orthopedic business. Excluding the impact of Stelara in Q1, the overall growth was in the double digits.

In terms of stock trend, the long-term upward trend started in January 2025 at $140.70 and reached $251.71 by March 2026, a rise of about 79%, followed by consolidation. Recently, daily candles show a bullish trend; technical analysis suggests short-term divergence is large, with a pullback to the 5-day moving average likely before another rally. Short-term resistance is near $130 (adjusted for ADR or stock split). Its beta is only 0.5–0.6, with a 62-year history of continuous dividend growth, and a dividend yield of about 3.0%, making it a natural haven for risk-averse funds.

Johnson & Johnson’s current investment value is supported by three overlapping reasons: the gradual resolution of litigation tail risks, diversification reducing dependence on a single product, and the healthcare sector’s defensive attribute after AI cooling. Unlike Micron’s high volatility and high expectations, JNJ’s core contradiction is not "whether it can grow," but "whether its valuation can expand." In the environment of high market levels and sector rotation, JNJ is expected to continue its gentle but steady upward trajectory.

IV. MMM—When the "Old Economy Champion" Faces New Litigation Storm

3M is the most cautionary among the five stocks, with recent movements illustrating a classic "bottom rebound + sudden event shock" pattern.

Fundamentally, in Q1 2026, revenue was $60.3 billion, net profit $65.3 billion (note: data units need verification, possibly in millions or thousands), reaffirming full-year guidance of about 4% total sales growth and 3% organic growth. Compared to a year ago when MMM was below $100, fundamentals have clearly recovered.

In stock performance, recent price is around $155, fluctuating between $151–$153; a break above $153 could test $155–$156, while a fall below $151 might target $148–$149 support. Technical ratings are overall neutral or slightly low, with high volatility and no clear entry/exit points.

However, the recent event-driven shock on May 28th changed the trend pace. The Australian government filed a lawsuit against 3M, claiming over $1.4 billion in damages, accusing its firefighting foam containing PFAS "permanent chemicals" of polluting 28 defense bases. This is the latest and largest overseas legal challenge 3M has faced recently, with environmental liabilities of PFAS casting a shadow again. As a result, 3M pre-market dropped 3.33% to $150.

3M’s situation reflects a common dilemma for "legacy industrial blue chips" in the current environment: fundamentals are recovering, but historical legal and environmental liabilities may suddenly reverse the trend. The key variables moving forward are: the actual scope of litigation impact (whether it triggers chain lawsuits globally), and progress in divesting PFAS-related businesses. Until the negative impact of this event is fully digested, it’s more prudent to stay on the sidelines with 3M.

V. TSM—Deep Moat of a Leader, AI-Driven Logic Still Steady

TSMC is currently the closest to a "long-term certain winner" among the five stocks, with the deepest moat. However, short-term, it also faces pressure from the Nasdaq and Philadelphia Semiconductor Index adjustments.

Fundamentally, in Q1 2026, revenue reached 1.13 trillion TWD (about $5.65B), up 35.1% YoY, setting a quarterly record for the fourth consecutive quarter; net profit was 572.48 billion TWD, up 58.3%, with high net margin. It is expected that in H2 2026, 3nm process prices will be raised again, with increases up to 15%, and possibly another 5–10% in 2027, reflecting its absolute monopoly position in advanced process technology. The company’s annual employee profit-sharing and dividends are expected to continue growing at least 30%, indicating confidence in future profitability.

In stock price, ADRs recently traded between $400–$420. On May 27th, closed at $412.32, up 1.93%, with volume up about 42%. Notably, despite the Philadelphia Semiconductor Index weakening on that day, TSMC ADR rose 2.52%, benefiting from Nvidia’s announcement of $150 billion in procurement from TSMC, and reflecting market recognition of TSMC’s long-term premium logic. Technical analysis suggests that if support holds near $273, it could be a good entry point for dips, awaiting further gains.

The core outlook for TSMC is based on the long-term demand for AI computing infrastructure. Among all semiconductor leaders, TSMC has the most certain high-end capacity monopoly and the strongest cash dividend foundation. Short-term uncertainties include: first, if Micron and other AI chip stocks pull back collectively, it could drag down the entire PHLX Semiconductor Index and TSMC; second, geopolitical risks could continue to suppress TSMC’s valuation premium. However, given TSMC’s current phase of quarterly revenue hitting new highs and net profit growing over 50% rapidly, the recent correction is more likely a long-term buying opportunity rather than a trend reversal signal.

VI. MRNA—Post-Pandemic "Gap Climb"

MRNA is the most unique among the five stocks—it is neither an AI computing beneficiary nor a traditional defensive pharma company, but a biotech firm undergoing a difficult transformation from a COVID-19 vaccine unicorn to a comprehensive mRNA platform company.

Fundamentally, in Q1 2026, revenue was $389 million, up 260%, with about 80% from international markets, mainly from COVID-19 vaccine sales in the UK and other markets, exceeding expectations by 54.51%. Whether revenue can sustain growth depends on the approval and commercialization speed of next-generation products like seasonal flu vaccines and tumor vaccines (mRNA-4157). However, GAAP net loss in Q1 was $3M, including about $878 million in major litigation settlement costs; even excluding this, the company remains in loss.

In stock performance, as of May 28th, it closed at $46.88, with daily fluctuations between $46.77–$48.35. The decline from its peak near $500 in 2021 is about 75%, but year-to-date, it has rebounded over 66%. Technical indicators show the 50-day moving average at about $49.14 as a short-term resistance, RSI around 54, MACD negative, overall neutral to weak. The recent rebound was driven by positive phase 3 flu vaccine data and hantavirus vaccine news, but sustainability remains to be seen. The company has completed a $1.34 billion share repurchase plan, signaling management’s attitude toward current valuation.

MRNA is a long-term option with significant potential. If the platform successfully expands into tumor immunotherapy, rare diseases, and other areas, it could unlock markets far beyond COVID vaccines. But in the short term, lacking stable profitability and with unresolved litigation risks, the current stock price near $47 more reflects 'platform transformation' premium rather than actual earnings. It’s a high-risk, high-reward speculative asset, more suitable for long-term investors willing to accept high volatility and betting on broad mRNA commercialization, rather than seeking certainty.

Overall strategic positioning
$MU ‌$JNJ ‌$MMM ‌
#交易CFD送黄金